Jiří H.
- Country
- Czechia
- Department
- Urology
Research Overview
- Open-Label Extension Study on Long-Term Safety of Enzalutamide in Prostate Cancer Patients from Previous Clinical Trials
- Randomized Controlled Trial of Nadofaragene Firadenovec Versus Observation in Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Phase 3 Randomized Trial of Nadofaragene Firadenovec with Gemcitabine, Docetaxel, or Pembrolizumab in BCG-Unresponsive High-Grade NMIBC
Data & Insights
Has run more than one trial at 30 of 144 partner sites.
Specializations
Oncology Focus
The investigator specializes in prostate cancer treatment and research, with particular emphasis on innovative therapeutic approaches in oncology.
- Advanced prostate cancer management
- Hormone therapy research
- Long-term cancer care
Demonstrates expertise in evaluating novel therapeutic agents for prostate cancer treatment.
Therapeutic Innovation
Focuses on investigating targeted therapies including darolutamide and enzalutamide for cancer treatment.
- Novel drug applications
- Treatment continuation protocols
- Clinical benefit assessment
Actively involved in evaluating long-term therapeutic outcomes in oncology patients.
Safety Assessment
Specializes in long-term safety evaluation of cancer treatments and therapeutic interventions.
- Treatment safety monitoring
- Extended therapy assessment
- Patient benefit analysis
Maintains focus on comprehensive safety data collection and analysis in cancer therapeutics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.